Track topics on Twitter Track topics that are important to you
STAT Plus: An appeals board recommended that Astellas be expelled for five years. The trade group, however, ignored the recommendation. https://buff.ly/2EtqUNl
An appeals board recommended that Astellas be expelled for five years. The trade group, however, ignored the recommendation.
Edison Investment Research - Pharmaceutical & healthcare - SymBio Pharmaceuticals: SymBio announced in October that it has begun preparations to establish its own sales organization to market Treakisym and other anticancer drugs in Japan after the marketing agreement with Eisai expires in December 2020. The announcement validates our decision earlier this year to adopt self-commercialization in Ja...
X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative drug discovery platform to the generation of novel small molecule therapeutics, announced today a drug discovery partnership with Almirall, S.A. (Almirall) to discover lead compounds for innovative and challenging targets with dermatology applications. Under the ...
Provides Global Clinical Development Expertise to Advance GFB-887 and Pipeline of Innovative Kidney Disease Treatments Goldfinch Bio, a biotechnology company focused on discovering and developing precision medicines for the treatment of genetically-driven kidney diseases, today announced the appointment of Frank S. Czerwiec, M.D., Ph.D. as Ch...
- The 2019 award celebrates two leading global regenerative medicine researchers Takeda Pharmaceutical Company Limited, (“Takeda”) (TSE:4502) and the New York Academy of Sciences announced today the Winners of the second annual Innovators in Science Award for their c
SummaryOtsuka Medical Devices Co Ltd Otsuka Medical Devices, a subsidiary of Otsuka Holdings Co Ltd, is a medical device manufacturing company. The company concentrates on revolutionary diagnostic and treatment technologies that find solutions in treating drugrefractory patients and intractable diseases. Its products include endoscopy, orthopedic implants, granulocyte apheresis columns, vascular i...
Basilea; Cresemba® U.S. sales performance triggers CHF 10M milestone payment from Astellas $BSLN https://globenewswire.com/news-release/2018/12/10/1664084/0/en/Basilea-Pharmaceutica-AG-Continued-strong-Cresemba-isavuconazole-U-S-sales-performance-trigger
Basilea; Cresemba® U.S. sales performance triggers CHF 10M milestone payment from Astellas $BSLN https://globenewswire.com/news-release/2018/12/10/1664084/0/en/Basilea-Pharmaceutica-AG-Continued-strong-Cresemba-isavuconazole-U-S-sales-performance-triggers-CHF-10-million-milestone-payment-to-Basilea.htm
Basilea Pharmaceutica AG / Basilea Pharmaceutica AG : Continued strong Cresemba® (isavuconazole) U.S. sales performance triggers CHF 10 million milestone payment to Basilea . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. Basel, Switzerland, December 10, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announc...
Edison Investment Research - Pharmaceutical & healthcare - SymBio Pharmaceuticals: SymBio announced in October that it has begun preparations to establish its own sales organisation to market Treakisym and other anticancer drugs in Japan after the marketing agreement with Eisai expires in December 2020. The announcement validates our decision earlier this year to adopt self-commercialisation in Ja...
#EISAI First Drug Candidate From Eisai-UCL Research Collaboration To Enter #Alzheimer's Disease Clinical Trials https://www.eisai.com/news/2018/news2018104.html …
Takeda will takeover Shire, after shareholders approved the proposed acquisition, and is expected to close in early 2019.
Astellas Pharma Inc 4503 Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment y...
Daiichi Sankyo Presents Updated Phase 1 Data for U3-1402 in Patients with HER3-Expressing Metastatic Breast Cancer #SABCS18 https://www.prnewswire.com/news-releases/daiichi-sankyo-presents-updated-phase-1-data-for-u3-1402-in-patients-with-her3-expressing-
Daiichi Sankyo Presents Updated Phase 1 Data for U3-1402 in Patients with HER3-Expressing Metastatic Breast Cancer #SABCS18 https://www.prnewswire.com/news-releases/daiichi-sankyo-presents-updated-phase-1-data-for-u3-1402-in-patients-with-her3-expressing-metastatic-breast-cancer-at-2018-san-antonio-breast-cancer-symposium-sabcs-300760690.h
Buying Shire in a merger valued at $58 billion today would enable Takeda to tap into the lucrative market for rare diseases https://on.wsj.com/2RwBrdr
a breakthrough inIf gene therapy lives up to its promise, it reallywill justify the song and dance
Takeda Pharmaceutical’s planned £46 billion ($58.5 billion) acquisition of Shire will proceed toward completion early next year as planned following approvals today by shareholders of both companies. Shire said today that 99.8% of its shareholders voted in favor of the blockbuster deal, while Takeda last night said “at least 88%” of its shareholders did likewise. […] The post Shire, T...
Takeda Pharmaceutical shareholders supported a deal to buy Shire, crushing opposition to derail the biggest overseas acquisition by a Japanese company.
Takeda shareholders back Shire purchase https://www.firstwordpharma.com/node/1609404 $SHP $SHPG
Vote paves way for Japan’s largest ever corporate takeover
Vote paves way for Japan’s largest ever corporate takeover
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) today announced the results of the shareholder votes at its Extraordinary General Meeti...
Although it was probably not in serious peril, shareholders of Japan’s Takeda Pharmaceutical voted to approve the acquisition of Dublin’s Shire. The deal is currently valued at $58 billion.